triiodothyronine (T3) / Uni-Pharma - LARVOL DELTA

Thy-Support: Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection (clinicaltrials.gov) - P2; N=5; Terminated; Sponsor: Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.; N=60 ➔ 5; Recruiting ➔ Terminated; Due to specific inclusion criteria no more subjects could be enrolled.

Enrollment change • Trial termination • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Thy-Support: Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection (clinicaltrials.gov) - P2; N=60; Recruiting; Sponsor: Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease

Triiodothyronine for the treatment of critically ill patients with COVID-19 infection (Thy-Support Study) Η τριϊωδοθυρονίνη για την θεραπεία των σοβαρά νοσούντων ασθενών με λοίμωξη από COVID-19 (μελέτη Thy-Support) (clinicaltrialsregister.eu) - P2; N=60; Ongoing; Sponsor: Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.

Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease

Thy-Support: Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection (clinicaltrials.gov) - P2; N=60; Not yet recruiting; Sponsor: Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.

Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease